摘要
目的探讨脂蛋白相关磷脂酶A2(Lp-PLA2)在缺血性卒中风险评估中的价值。方法方便选取2015年1月—2017年7月该院收治的130例缺血性卒中患者为实验组,另择取同期130名健康体检者为对照组,于清晨空腹抽取静脉血液样本检测并观察两组血清Lp-PLA2水平差异,观察实验组不同TOAST分型、不同脑梗死面积及不同神经功能缺损患者的血清Lp-PLA2水平。结果实验组Lp-PLA2(317.4±106.2)ng/m L高于对照组,比较差异有统计学意义(P<0.05)。Logistic回归分析Lp-PLA2为缺血性卒中危险因素。LAA患者Lp-PLA2(381.4±112.6)ng/m L,高于CE、SAO患者,重度神经功能缺损患者Lp-PLA2(375.0±108.8)ng/m L,高于轻中度患者,比较差异有统计学意义(P<0.05)。结论 Lp-PLA2对缺血性脑卒中具有警示作用,可用于早期患病风险评估及病理学分型和病情严重程度的判断,具备临床推广价值。
Objective To study the value of lipoprotein-associated phospholipase a2 in the risk evaluation of ischemic stroke. Methods 130 cases of patients with Ischemic stroke admitted and treated in our hospital from January 2015 to July2017 were convenient selected as the experimental group, while 130 cases of healthy physical examination were selected as the control group, and the vein blood samples were extracted in the morning at fasting and the difference in the serum LpPLA2 level of the two groups was observed and the serum Lp-PLA2 level of patients of different TOAST types, different cerebral infarction area and different nerve function defect conditions in the experimental group was observed. Results The Lp-PLA2 level in the experimental group was(317.4±106.2) ng/m L, which was higher than that in the control group, and the difference was statistically significant(P<0.05), and the Logistic regression analysis showed that Lp-PLA2 was the risk factor of ischemic stroke, and the Lp-PLA2 of LAA patients was(381.4±112.6) ng/m L, which was higher than that of CE patients and SAO patients, and the Lp-PLA2 of patients with severe nerve function defect was(375.0±108.8) ng/m L, which was higher than that of mild and moderate patients and the differences were statistically significant(P<0.05). Conclusion The Lp-PLA2 plays a caution role in the ischemic stroke, which can be used in the evaluation of disease risks and determination of pathological typing and disease severity, and it is of clinical promotion value.
出处
《中外医疗》
2017年第31期31-33,共3页
China & Foreign Medical Treatment
关键词
脂蛋白相关磷脂酶A2
缺血性卒中
风险评估
Lipoprotein-associated phospholipase A2
Ischemic stroke
Risk evaluation
